Merck is trading 10.44% up now at $149.42 after Merck and Moderna announced positive Phase 3 INTerpath-001 results for intismeran combined with Keytruda.
- The regimen met primary recurrence-free-survival and key secondary distant-metastasis-free-survival endpoints versus Keytruda alone in resected high-risk melanoma patients.
- This is the first positive Phase 3 readout for an individualized mRNA cancer therapy.
- The clinical catalyst drives the gain; broader healthcare strength supports it. Trading activity is elevated; volume data was not provided.